Literature DB >> 8663051

Self-activation of recombinant human lysosomal procathepsin D at a newly engineered cleavage junction, "short" pseudocathepsin D.

B M Beyer1, B M Dunn.   

Abstract

To obtain a recombinant model of human cathepsin D with kinetic properties that are identical with native human liver enzyme, we have addressed the significant differences in structure and catalytic function between naturally occurring enzyme and bacterially derived pseudocathepsin D. Human procathepsin D was expressed in a baculovirus system to obtain correctly folded, glycosylated enzyme that upon acidification completely converts to the active intermediate, pseudocathepsin D. The oligosaccharide moieties of this recombinant enzyme contributed to about 5% of the apparent molecular mass of the enzyme, and the carbohydrate composition was quite similar to the native material. However, specificity constants (kcat/Km) of this glycosylated pseudoform for several synthetic chromogenic substrates were considerably less (33%-50%) than those for the native enzyme and were virtually identical with those observed with nonglycosylated pseudocathepsin D. A cleavable junction suitable for self-processing at the normal maturation point of human cathepsin D was engineered into procathepsin D according to known specificity requirements of this enzyme, and the construct was expressed using baculovirus. Following experiments that demonstrated that the new proenzyme failed to process to the expected point, the new cleavage junction was moved 6 residues toward the amino terminus of procathepsin D and expressed in Escherichia coli. After refolding, the protein containing the newly engineered junction self-processed, generating a shortened mutant form of pseudocathepsin D that is 6 residues longer at the amino terminus than the native material. The kinetic properties of this newly engineered pseudoform proved to be identical with those of the native enzyme, thus establishing an improved recombinant model for this important aspartic proteinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663051     DOI: 10.1074/jbc.271.26.15590

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Cathepsin D: Regulation in mammary gland remodeling, misregulation in breast cancer.

Authors:  Evette S Radisky
Journal:  Cancer Biol Ther       Date:  2010-09-30       Impact factor: 4.742

2.  Modification of the substrate specificity of porcine pepsin for the enzymatic production of bovine hide gelatin.

Authors:  C A Galea; B P Dalrymple; R Kuypers; R Blakeley
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

3.  Active site specificity of plasmepsin II.

Authors:  J Westling; P Cipullo; S H Hung; H Saft; J B Dame; B M Dunn
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

4.  Prime region subsite specificity characterization of human cathepsin D: the dominant role of position 128.

Authors:  B M Beyer; B M Dunn
Journal:  Protein Sci       Date:  1998-01       Impact factor: 6.725

5.  Electrostatic switches that mediate the pH-dependent conformational change of "short" recombinant human pseudocathepsin D.

Authors:  Nathan E Goldfarb; Minh T Lam; Arjo K Bose; Ambar M Patel; Alexander J Duckworth; Ben M Dunn
Journal:  Biochemistry       Date:  2005-12-06       Impact factor: 3.162

6.  Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.

Authors:  Peng Liu; Melissa R Marzahn; Arthur H Robbins; Hugo Gutiérrez-de-Terán; David Rodríguez; Scott H McClung; Stanley M Stevens; Charles A Yowell; John B Dame; Robert McKenna; Ben M Dunn
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

7.  Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei.

Authors:  Peng Liu; Arthur H Robbins; Melissa R Marzahn; Scott H McClung; Charles A Yowell; Stanley M Stevens; John B Dame; Ben M Dunn
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.